請輸入關鍵字
請輸入關鍵字
訂購
*國家
中國
美國
中國香港
中國澳門
中國台灣
阿爾巴尼亞
阿爾及利亞
阿根廷
阿拉伯聯合酋長國
阿魯巴
阿曼
阿塞拜疆
阿森鬆島
埃及
埃塞俄比亞
愛爾蘭
愛沙尼亞
安道爾
安哥拉
安圭拉
安提瓜和巴布達
奧地利
奧蘭群島
澳大利亞
巴巴多斯
巴布亞新幾內亞
巴哈馬
巴基斯坦
巴拉圭
巴勒斯坦領土
巴林
巴拿馬
巴西
白俄羅斯
百慕大
保加利亞
北馬裏亞納群島
貝寧
比利時
冰島
波多黎各
波蘭
波斯尼亞和黑塞哥維那
玻利維亞
伯利茲
博茨瓦納
不丹
布基納法索
布隆迪
朝鮮
赤道幾內亞
丹麥
德國
迪戈加西亞島
東帝汶
多哥
多米尼加共和國
多米尼克
俄羅斯
厄瓜多爾
厄立特裏亞
法國
法羅群島
法屬波利尼西亞
法屬圭亞那
法屬南部領地
梵蒂岡
菲律賓
斐濟
芬蘭
佛得角
福克蘭群島
岡比亞
剛果(布)
剛果(金)
哥倫比亞
哥斯達黎加
格恩西島
格林納達
格陵蘭
格魯吉亞
古巴
瓜德羅普
關島
圭亞那
哈薩克斯坦
海地
韓國
荷蘭
荷屬加勒比區
荷屬聖馬丁
黑山
洪都拉斯
基裏巴斯
吉布提
吉爾吉斯斯坦
幾內亞
幾內亞比紹
加拿大
加納
加納利群島
加蓬
柬埔寨
捷克
津巴布韋
喀麥隆
卡塔爾
開曼群島
科科斯(基林)群島
科摩羅
科索沃
科特迪瓦
科威特
克羅地亞
肯尼亞
庫克群島
庫拉索
拉脫維亞
萊索托
老撾
黎巴嫩
立陶宛
利比裏亞
利比亞
聯合國
列支敦士登
留尼汪
盧森堡
盧旺達
羅馬尼亞
馬達加斯加
馬恩島
馬爾代夫
馬耳他
馬拉維
馬來西亞
馬裏
馬其頓
馬紹爾群島
馬提尼克
馬約特
毛裏求斯
毛裏塔尼亞
美國本土外小島嶼
美屬薩摩亞
美屬維爾京群島
蒙古
蒙特塞拉特
孟加拉國
秘魯
密克羅尼西亞
緬甸
摩爾多瓦
摩洛哥
摩納哥
莫桑比克
墨西哥
納米比亞
南非
南極洲
南喬治亞和南桑威奇群島
南蘇丹
瑙魯
尼加拉瓜
尼泊爾
尼日爾
尼日利亞
紐埃
挪威
諾福克島
帕勞
皮特凱恩群島
葡萄牙
日本
瑞典
瑞士
薩爾瓦多
薩摩亞
塞爾維亞
塞拉利昂
塞內加爾
塞浦路斯
塞舌爾
沙特阿拉伯
聖巴泰勒米
聖誕島
聖多美和普林西比
聖赫勒拿
聖基茨和尼維斯
聖盧西亞
聖馬丁島
聖馬力諾
聖皮埃爾和密克隆群島
聖文森特和格林納丁斯
斯裏蘭卡
斯洛伐克
斯洛文尼亞
斯瓦爾巴和揚馬延
斯威士蘭
蘇丹
蘇裏南
所羅門群島
索馬裏
塔吉克斯坦
泰國
坦桑尼亞
湯加
特克斯和凱科斯群島
特裏斯坦-達庫尼亞群島
特立尼達和多巴哥
突尼斯
圖瓦盧
土耳其
土庫曼斯坦
托克勞
瓦利斯和富圖納
瓦努阿圖
危地馬拉
委內瑞拉
文萊
烏幹達
烏克蘭
烏拉圭
烏茲別克斯坦
希臘
西班牙
西撒哈拉
新加坡
新喀裏多尼亞
新西蘭
匈牙利
休達及梅利利亞
敘利亞
牙買加
亞美尼亞
也門
伊拉克
伊朗
以色列
意大利
印度
印度尼西亞
英國
英屬維爾京群島
英屬印度洋領地
約旦
越南
讚比亞
澤西島
乍得
直布羅陀
智利
中非共和國
*省份
*城市
*姓名
*電話
*單位
*職位
*郵箱
*請輸入驗證碼
*驗證碼
B-hPD-1/hPD-L1/hTNFR2 mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)BcgenCd274tm1(CD274)BcgenTnfrsf1btm1(TNFRSF1B)Bcgen/Bcgen
Common Name  B-hPD-1/hPD-L1/hTNFR2 mice
Background C57BL/6 Catalog number  130849
Related Genes 
PD-1 (Programmed death-1) 

CD274 (CD274 antigen)

TNFRSF1B (Tumor necrosis factor receptor superfamily, member 1b)

NCBI Gene ID
18566,60533,21938

Phenotypic analysis


Protein expression analysis in T cells


from clipboard


Strain specific PD-1, PD-L1 and TNFR2 expression analysis in homozygous B-hPD-1/hPD-L1/hTNFR2 (H/H) mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hPD-L1/hTNFR2 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1, anti-PD-L1 and anti-TNFR2 antibody. Mouse PD-1, PD-L1 and TNFR2 were detectable in WT mice. Human PD-1, PD-L1 and TNFR2 were exclusively detectable in homozygous B-hPD-1/hPD-L1/hTNFR2 but not WT mice.


Protein expression analysis in Treg cells


from clipboard


Strain specific PD-1, PD-L1 and TNFR2 expression analysis in homozygous B-hPD-1/hPD-L1/hTNFR2 (H/H) mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hPD-L1/hTNFR2 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1, anti-PD-L1 and anti-TNFR2 antibody. Mouse PD-1, PD-L1 and TNFR2 were detectable in WT mice. Human PD-1, PD-L1 and TNFR2 were exclusively detectable in homozygous B-hPD-1/hPD-L1/hTNFR2 but not WT mice.


Analysis of blood leukocytes cell subpopulations in B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Analysis of spleen leukocytes cell subpopulations in B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Analysis of lymph node leukocytes cell subpopulations in B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Analysis of blood, spleen and lymph node leukocytes cell subpopulations in B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Analysis of blood, spleen and lymph node leukocytes cell subpopulations by FACS. Blood, spleen and lymph node leukocytes cell were isolated from female mice in the panel(n=3, 6 week-old). Flow cytometry analysis was performed to assess leukocyte subpopulations. Percent of T, B, NK, Granulocytes, Monocyte, DC and macrophage cells in homozygous B-hPD-1/hPD-L1/hTNFR2 mice were similar to those in the C57BL/6 mice, demonstrating that the humanized mouse does not change the overall development, differentiation or distribution of these cell types in blood, spleen and lymph node.


Analysis of blood, spleen, lymph node T cell subpopulations in B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Analysis of blood, spleen and lymph node T cell subpopulations in B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Analysis of blood, spleen and lymph node T cell subpopulations by FACS. Blood, spleen and lymph node leukocytes cell were isolated from female mice in the panel(n=3, 6 week-old). Flow cytometry analysis was performed to assess leukocyte subpopulations. Percent of CD4+T, CD8+T and Tre cells in homozygous B-hPD-1/hPD-L1/hTNFR2 mice were similar to those in the C57BL/6 mice, demonstrating that the humanized mouse does not change the overall development, differentiation or distribution of these cell types in blood, spleen and lymph node.


Blood routine test of B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Complete blood count (CBC). Blood from C57BL/6 and B-hPD-1/hPD-L1/hTNFR2 mice (n=5, 6 week-old, female) were collected and analyzed for CBC. Any measurement of B-hPD-1/hPD-L1/hTNFR2 mice in the panel were similar to C57BL/6, indicating that humanized mouse does not change blood cell composition and morphology. Values are expressed as mean ± SEM.


Blood chemistry of B-hPD-1/hPD-L1/hTNFR2 mice


from clipboard


Blood chemistry tests of B-hPD-1/hPD-L1/hTNFR2 mice. Serum from C57BL/6 and B-hPD-1/hPD-L1/hTNFR2 mice (n=5, 6 week-old, female) were collected and analyzed for levels of ALT, AST and other indicators in the panel. There was no differences on either measurement between C57BL/6 and humanized mouse, indicating that humanized mouse does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.


Combination therapy of anti-human PD-1 and anti-human TNFR2 antibody

from clipboard


Antitumor activity of anti-human PD-1 antibody combined with anti-human TNFR2 antibody in B-hPD-1/hPD-L1/hTNFR2 mice. (A) Anti-human PD-1 antibody combined with anti-human TNFR2 antibody inhibited hPD-L1 MC38 tumor growth B-hPD-1/hPD-L1/hTNFR2 mice. All antibodies used in the experiments were prepared in-house. hPD-L1 MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hTNFR2 mice (female, 6-7-week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with human PD-1 antibody and human hTNFR2 antibodies (in house) with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of PD-1 and hTNFR2 antibodies shows more inhibitory effects than individual groups, demonstrating that B-hPD-1/hPD-L1/hTNFR2 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of  hTNFR2 antibodies and hPD-1 antibodies. Values are expressed as mean ± SEM.